These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 23070385)

  • 21. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
    Barkin J; Roehrborn CG; Siami P; Haillot O; Morrill B; Black L; Montorsi F;
    BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study.
    Becher E; Roehrborn CG; Siami P; Gagnier RP; Wilson TH; Montorsi F
    Prostate Cancer Prostatic Dis; 2009; 12(4):369-74. PubMed ID: 19901936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Solifenacin or mirabegron could improve persistent overactive bladder symptoms after dutasteride treatment in patients with benign prostatic hyperplasia.
    Maeda T; Kikuchi E; Hasegawa M; Ishioka K; Hagiwara M; Miyazaki Y; Shinojima T; Miyajima A; Oya M
    Urology; 2015 May; 85(5):1151-1155. PubMed ID: 25770728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple Therapy with Tamsulosin, Dutasteride, and Imidafenacin for Benign Prostatic Hyperplasia in Patients with Overactive Bladder Symptoms Refractory to Tamsulosin: Subgroup Analyses of the DIrecT Study.
    Yamanishi T; Asakura H; Seki N; Tokunaga S
    Urol Int; 2021; 105(9-10):817-825. PubMed ID: 33690238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
    Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
    Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between overactive bladder symptoms and quality of life in Japanese male patients: focus on nocturia.
    Takao T; Tsujimura A; Kiuchi H; Takezawa K; Okuda H; Yamamoto K; Fukuhara S; Miyagawa Y; Nonomura N
    Urology; 2013 Jul; 82(1):189-93. PubMed ID: 23642937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of intraprostatic architecture and regrowth velocity for considering discontinuation of dutasteride after combination therapy with an alpha blocker: a prospective, pilot study.
    Shindo T; Hashimoto K; Shimizu T; Itoh N; Masumori N
    Korean J Urol; 2015 Apr; 56(4):305-9. PubMed ID: 25874044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy.
    Kuo HC; Liu HT
    Scand J Urol Nephrol; 2009; 43(3):206-11. PubMed ID: 19308807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia.
    Hong SK; Min GE; Ha SB; Doo SH; Kang MY; Park HJ; Yoon CY; Jeong SJ; Byun SS; Lee SE
    BJU Int; 2010 Apr; 105(7):970-4. PubMed ID: 19793378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of dutasteride on lower urinary tract symptoms and general health in men with benign prostatic hypertroplasia and hypogonadism: a prospective study.
    Shigehara K; Koh E; Sakamoto J; Yaegashi H; Izumi K; Ueno S; Kitagawa Y; Maeda Y; Kadono Y; Konaka H; Mizokami A; Nakashima T; Namiki M
    Aging Male; 2014 Mar; 17(1):51-6. PubMed ID: 24134649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin].
    Utsunomiya N; Matsumoto K; Tsunemori H; Muguruma K; Kawakita M; Kamiyama Y; Kanamaru S; Ito N; Tsukazaki H; Shirahase T; Takahashi T
    Hinyokika Kiyo; 2016 Jul; 62(7):341-7. PubMed ID: 27569351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Araki K; Naya Y; Inahara M; Suzuki F; Ota S; Tsuji H; Mikami K; Yanagisawa M; Awa Y; Suzuki H
    Int J Urol; 2014 Aug; 21(8):815-9. PubMed ID: 24735081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration.
    Chapple CR; Herschorn S; Abrams P; Wang JT; Brodsky M; Guan Z
    BJU Int; 2010 Nov; 106(9):1332-8. PubMed ID: 20497416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF; Jiang YH; Kuo HC
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Slow Stream Is Pathophysiologically Related to a Poor Response to α1-Adrenoceptor Therapy in the Treatment of Storage Symptoms Associated With Benign Prostatic Hyperplasia.
    Matsukawa Y; Takai S; Asai K; Kasugai S; Narita H; Komatsu T; Kashiwagi Y; Kato M; Yamamoto T; Gotoh M
    Urology; 2015 Sep; 86(3):558-64. PubMed ID: 26189139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
    Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
    Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.
    Lin VC; Liao CH; Wang CC; Kuo HC
    J Formos Med Assoc; 2015 Sep; 114(9):865-71. PubMed ID: 24064231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
    Tsukamoto T; Masumori N; Rahman M; Crane MM
    Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.